Merck & Co Inc

Merck’s Phase 3 trial of Enlicitide Decanoate shows 48.7% LDL‑C reduction in HeFH patients, offering a promising new therapy for unmet cardiovascular needs.

Merck’s Q3 earnings hit $5.23B, powered by Keytruda and Januvia, and the firm’s new $120M Blackstone partnership pushes sacituzumab‑tirumotecan toward Phase 3.

Merck’s Q3 2025 earnings beat expectations, driven by KEYTRUDA’s EU launch and a strong oncology pipeline, positioning the company for growth amid pricing pressures.

Merck & Co Inc has reported positive data for its two-drug HIV regimen, doravirine and islatravir, which demonstrates non-inferiority to a leading single-tablet regimen and offers a potential cost-saving advantage for payers.

Merck & Co. has partnered with Danish biotech firm Evaxion A/S to develop and commercialize Evaxion’s vaccine candidate EVX-B3, with the potential to generate significant milestone payments and royalty income as the global vaccine market is projecte…

Merck & Co Inc has announced positive results from a Phase 3 trial of its lipid therapy, Enlicitide Decanoate, which demonstrated its efficacy in lowering LDL cholesterol in patients with hypercholesterolemia.

Merck & Co Inc’s stock remains steady, poised for growth as the demand for minimal residual disease testing increases due to rising cancer cases and advancements in molecular diagnostics.

Merck & Co Inc has demonstrated resilience in a turbulent market, impressing analysts with its strong performance and well-positioned business model.

Merck & Co Inc’s stock price remains stable, with investors awaiting the company’s quarterly financial report for insight into its current performance and future prospects.

Merck & Co Inc. has unveiled a comprehensive restructuring plan to address declining sales and profits, aiming to save $3 billion annually and redirect funds towards growth areas and new medicine development.